Study on the Mechanism of Action of STAT3 in the Drug Resistance of Gastric Cancer Cells

Author:

Di Ji12,Jiang Bo23,Shang Hao4,Yang Xin5,Zhang Chengwu6,Shi Xiali7,Chai Yan2ORCID

Affiliation:

1. Department of Medical Oncology, Affiliated Hospital of Qinghai University, XiNing 810012, China

2. School of Clinical Medicine, Tsinghua University, Beijing 100084, China

3. Beijing Tsinghua Changgung Hospital, Beijing 100084, China

4. Department of General Surgery, The Second Affiliated Hospital, Xi'an Jiaotong University School of Medicine, Xi’an, Shaanxi 710004, China

5. Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China

6. Department of Surgical Oncology, Affiliated Hospital of Qinghai University, XiNing 810012, China

7. Department of Anesthesiology and Surgery, The Second Affiliated Hospital, Xi’an Jiaotong University School of Medicine, Xi’an, Shaanxi 710004, China

Abstract

Gastric cancer is the most common digestive tract malignancy in China and has a poor prognosis, with a 5-year overall survival rate of only 35.1%. Because its early symptoms are not obvious and early diagnosis is complicated, there is an urgent need to find biological targets for diagnosis and treatment. This research detected the expression of STAT3 in gastric cancer tissues and adjacent tissues by Western blot and immunohistochemical experiments and conducted corresponding basic experiments to explore the role of STAT3 in inhibiting the proliferation of cisplatin-resistant gastric cancer cells and promoting their apoptosis, including the construction of cisplatin-resistant gastric cancer cell line, the knock-out STAT3 in drug-resistant gastric cancer cells by CRISPR-Cas9, and the comparison of the proliferation and apoptosis of drug-resistant cells and drug-resistant cells STAT3(-). The mechanism provides a possible intervention target for clinically improving the prognosis of patients with cisplatin-resistant gastric cancer.

Funder

Project of Technology Department of Qinghai Province

Publisher

Hindawi Limited

Subject

Radiology, Nuclear Medicine and imaging

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3